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Efficacy of azithromycin for prevention of bronchopulmonary
dysplasia (BPD)
Manizheh Mostafa GHAREHBAGHI1, Ali PEIROVIFAR2, Mortaza GHOJAZADEH3, Majid MAHALLEI1

Aim: Bronchopulmonary dysplasia (BPD) remains one of the most serious and challenging complications in premature
infants. This study was conducted to evaluate the efficacy of azithromycin in the prevention of BPD in very low birth
weight preterm infants
Materials and methods: Preterm neonates with birth weight less than 1500 g were enrolled in a prospective randomized
controlled clinical trial. One hundred eight neonates were randomly allocated to the intervention group (n = 56) or
control group (n = 52). The intervention group received oral azithromycin 10 mg/kg for 1 week followed by 5 mg/kg
for another week. The outcome measures were development of BPD at 28 days of birth and 36 weeks postmenstrual age
(PMA).
Results: The mean gestational age of the studied patients was 29.2 ± 3.6 weeks and their birth weight was 1173.9 ± 261
g. There was no significant difference in participants’ sex distribution or their gestational age between the 2 groups.
Twenty-one (43%) of the 52 patients in the control group met the definition of BPD at 28 days while 14 (25%) did in the
azithromycin group (P = 0.04). Twelve patients were oxygen dependent (moderate to severe BPD) at 36 weeks PMA; 9
of them were from the control group (P = 0.04).
Conclusion: Our study suggests that azithromycin is effective in reducing the incidence of BPD in very low birth weight
infants. More studies are needed with large numbers of patients before recommending routine use of this relatively safe
drug for prevention of BPD.
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Introduction
Bronchopulmonary dysplasia (BPD) was initially
described by Northway in 1967 as an evolving
radiologic pattern of lung injury among premature
infants who are mechanically ventilated and receiving
supplemental oxygen (1). Currently, this severe form
of chronic lung disease is less common and has been
replaced by a milder form of the disease. This new
form of BPD is associated with a disruption of lung
organogenesis and impaired pulmonary function
during the first years of life (2,3). This milder form

of lung damage occurs in infants who initially have
only mild pulmonary disease and do not require
high airway pressures or FiO2 and demonstrate
a different radiologic picture that shows diffuse
haziness and a fine lacy pattern (4). The incidence of
BPD in premature infants with respiratory distress
syndrome (RDS) who receive mechanical ventilation
is inversely related to gestational age and birth weight
(5). Mechanical ventilation with positive pressure
and prematurity have been considered the most
important factors in the pathogenesis of BPD; other
factors that can contribute to the pathogenesis of BPD
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are oxygen toxicity, pulmonary or systemic infections,
pulmonary vascular damage, and pulmonary edema
induced by patent ductus arteriosus or excessive fluid
administration (6-10). There is increasing evidence
for the role of antenatal and postnatal infections in
the development of BPD. Several studies suggested
an association between Ureaplasma urealyticum
tracheal colonization and the development of severe
respiratory failure and BPD in very low birth weight
infants (11-14).
When considering Ureaplasma urealyticum as
a cause of BPD, it would be reasonable to expect
prevention of BPD by antibiotic treatment against
Ureaplasma. Macrolide antibiotics have antiinflammatory actions that include inhibiting proinflammatory cytokines (such as IL-1, IL-6, and
TNF-α), inhibiting inflammatory transcription
factors (NF-ΚB), acting as free radical scavengers,
inhibiting neutrophil chemotaxis, and inhibiting
superoxide generation. Azithromycin is a macrolide
that modulates neutrophil function, and reduces
chemokine and interleukin-6 (15). We conducted a
clinical trial to evaluate the efficacy of azithromycin
in the prevention of BPD in very low birth weight
preterm infants.
Materials and methods
This was a randomized controlled clinical trial carried
out at the neonatal intensive care (NICU) unit of AlZahra teaching hospital, Tabriz, Iran, a university
level III neonatal center in the northwest of Iran, from
April 2010 to December 2010. Consecutive preterm
newborn infants of gestational age less than 32 weeks
and birth weight less than 1500 g that were admitted
to the NICU were eligible for enrollment into our
study. Infants with congenital malformations,
known syndromes, or chromosomal anomalies and
infants with signs compatible with the diagnosis of
necrotizing enterocolitis (NEC) in the first week of
life were excluded from this study. Tabriz University
of Medical Sciences ethics committee approved the
study. Informed parental consent was obtained when
the infant met the inclusion criteria. Gestational age
was determined by the last menstrual period and first
or second trimester ultrasonography when available.
Accuracy of gestational age determination was
confirmed by Ballard assessment (16). After birth and

admission to the NICU, all infants were continuously
evaluated for the presence of respiratory distress
syndrome and need for supplemental oxygen.
Infants with respiratory distress and grunting
were initially placed on continuous positive airway
pressure (CPAP) of 5-7 cm H2O. Premature infants
who needed a fraction of inspired oxygen (FiO2)
more than 40% to maintain adequate oxygenation
and radiologic findings compatible with RDS were
intubated for surfactant administration with the
INSURE method. Patients were randomly allocated
into 2 groups. Randomization was performed
1:1 using a computer-generated randomization
list prepared by an independent statistician not
involved in the rest of the investigation. Based
on the list, sequentially numbered sealed opaque
envelopes containing cards with group assignment
were prepared. The intervention group received
oral azithromycin (Zithromax, Pfizer, Italy) 10 mg/
kg/day initiated from day 7 of birth for 1 week
followed by 5 mg/kg/day oral azithromycin for an
additional 1 week. The drug was discontinued if
the infants were weaned from supplemental oxygen
and discharged home before completing the 2-week
treatment course. The primary outcomes were
development of BPD at 28 days of life and oxygen
dependency at 36 weeks postmenstrual age (PMA).
Secondary outcomes included length of hospital stay
and duration of oxygen dependency. The criteria
for diagnosis of BPD were continued dependency
on supplemental oxygen at 28 days of life or longer
with a compatible chest radiograph. Definition of
moderate to severe BPD in preterm neonates with
gestation age less than 32 weeks was dependence
on supplemental oxygen at 36 weeks PMA (17). The
diagnosis of BPD was recorded by 2 independent
senior attending neonatologists who did not know
the group assignment of the neonates. The respiratory
nurses were also blinded to the patient groups. The
same respiratory management protocol was used for
treatment of studied patients. The fraction of inspired
oxygen was adjusted to maintain pulse oximetry
saturation between 90% and 92%. Diagnosis of
sepsis was based on the presence of clinical signs of
sepsis accompanied by positive blood culture. Patent
ductus arteriosus (PDA) was diagnosed based on
clinical signs confirmed by echocardiography done
by an expert pediatric cardiologist. Ibuprofen 10 mg/
1071
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kg followed by 5 mg/kg/day for 2 consecutive days
were used to treat echographic hemodynamically
significant PDA. Liver function tests were performed
at 21-28 days of life in patients of both groups.
Hearing screening was done at a follow-up visit.
In calculating the sample size required for this
randomized study, it was considered that, in a
previous pilot study including very low birth weight
premature infants who had BPD in our center, 41% of
the patients were satisfied after 1 month. A difference
of 30% in the satisfaction rate between the 2 study
groups was considered clinically relevant. To have
an 80% chance of detecting such a difference at an
overall statistical significance level of 5%, 50 patients
per group were required. Allowing for dropouts, the
aim was to recruit a total of about 128 patients.
Statistical analysis
The demographic characteristics of neonates were
compared by using Student’s t test, chi-square test,
or Fisher’s exact test as appropriate. Student’s t test
or Mann-Whitney rank sum test and chi-square test
were used to compare between the 2 study groups.
P < 0.05 was considered statistically significant. Data
were analyzed using Sigma Stat version 3.5 and SPSS
version 17.0/Win.

Results
One hundred twenty-eight infants weighing ≤ 1500
g at birth were admitted to the NICU during the
study period. Twenty patients who met the weight
criteria were excluded from the study: 11 patients
died within the first week of life and 2 developed
signs compatible with NEC in the first week of life.
Two patients had congenital malformations. The
parents refused to grant consent for 5 patients. One
hundred eight infants were enrolled in the study and
randomly categorized into 2 groups. The intervention
group consisted of 56 infants and the control group
52 neonates. The mean gestational age of the studied
patients was 29.2 ± 3.6 weeks and their birth weight
was 1173.9 ± 261 g. The comparison between the 2
studied groups revealed no significant difference in
participants’ sex distribution or their gestational age
and maternal risk factors as shown in Table 1. There
was a positive history of preeclampsia in 8 infants
who developed BPD (P = 0.12). Regarding the need
for surfactant replacement therapy, there was no
significant difference among patients in the 2 groups
[33 neonates (58.9%) in the intervention group vs.
30 neonates (57.7%) in the control group (P = 0.97)].
Thirteen infants (23.2%) underwent mechanical
ventilation in the intervention group and 11 (21.1%)

Table 1. Comparison of some demographic characteristics of neonates in the intervention and control groups.

Group

Intervention
(N = 56)

Control
(N = 52)

P value

29.8 ± 2.5

29.7 ± 2.3

0.93

1177.1 ± 221

1212.9 ± 235.7

0.42

34/22

35/17

0.54

1 min

5.8 ± 2.3

6.5 ± 1.9

0.09

5 min

8 ± 1.5

8.4 ± 1.4

0.007

11(%)

6 (%)

0.29

19 (34%)

14 (27%)

0.27

4

3

0.77

Variable
Gestational age (weeks)
Birth weight (g)
Sex (m/f)
Apgar score

PROM
preeclampsia
IUGR
PROM = Preterm rupture of membranes
IUGR = intrauterine growth retardation
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in the control group (P = 0.49). CPAP was used in
40 infants (73%) in the intervention group and in 39
(75%) in the control group (P = 0.99). Vitamin A was
administered to 16 (30.7%) neonates in the control
group and to 16 (23.5%) in the azithromycin group
(P = 0.08). Treatment with aminophylline was given
in 38 (71.1%) and 42 (71.4%) patients in the control
and intervention groups, respectively (P = 0.83).
Blood culture was positive in 5 neonates; 3 of them
were in the azithromycin group (P = 0.7). The use of
other antibiotics was positive in 64 patients (36 in the
intervention group and 28 in the control group) (P
= 0.45).
C-reactive protein (CRP) was measured
qualitatively in 105 neonates and it was positive in
10 patients. Nine infants with positive CRP were in
intervention group (P = 0.01). Three patients with
positive CRP developed BPD (P = 0.86).
Five patients in the intervention group were
discharged before the age of 21 days and the duration
of treatment with azithromycin was less than 2 weeks.
The mean duration of azithromycin therapy in the
intervention group was 13.57 ± 1.52 days. The mean
duration of hospital stay in the intervention group

was 38.4 ± 21 days and in the control group it was
36.1 ± 27.2 days without a significant difference (P
= 0.62). Twenty-one (43%) of the 52 patients in the
control group met the definition of BPD at 28 days
whereas 14 (25%) did in the intervention group (P =
0.04). Twelve patients had BPD at 36 weeks PMA; 9
of them were from the control group (P = 0.04). The
mean duration of need for supplemental oxygen was
17.7 ± 2.8 and 23.95 ± 4.2 days in the intervention
and control groups, respectively (P = 0.01). The mean
FiO2 needed at 28 days after birth for infants in the
intervention and control groups was 23.9 ± 0.7 and
26.2 ± 1.1, respectively (P = 0.02). PDA was diagnosed
in 33 infants; 18 of them were in the azithromycin
group (P = 0.29). Hemodynamically significant
PDA needing ibuprofen was seen in 18 patients; 10
of them developed BPD (P = 0.02). The incidence
of intraventricular hemorrhage, NEC, patent ductus
arteriosus and abnormal hearing screen was not
significantly different between the 2 groups (Table 2).
The rate of antenatal steroid treatment to induce lung
maturation did not differ significantly between the 2
groups [31 infants (59.6%) in the control group and
34 (60.7%) in the intervention group (P = 0.90)].

Table 2. Comparison the complications of prematurity among patients in the 2 groups.

Group

Intervention
(N = 56)

Control
(N = 52)

P value

I

17 (33.5%)

17 (32.7%)

0.32

II

-

2 (3.8%)

0.20

III

-

1 (1.9%)

0.24

IV

-

-

Complication
IVH
Grade

NEC

1 (1.8%)

-

PDA

20 (35.7%)

13 (25%)

0.29

Sepsis

3 (5.3%)

2 (3.8%)

0.99

Vomiting

9 (16.1%)

7 (13.5%)

0.79

Abnormal hearing screen
SGOT

2 (3.6%)

3 (5.8%)

0.58

61.1 ± 13.7

36.6 ± 2.9

0.14

SGPT

15.5 ± 2.4

12.8 ± 2.2

0.43

ALKP

766.9 ± 47

736.8 ± 66.5

0.71

IVH = intraventricular hemorrhage, NEC = necrotizing enterocolitis, PDA = patent ductus arteriosus,
ALKP = alkaline phosphates
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Discussion
BPD was diagnosed in 25% of infants who received
azithromycin and in 43% of infants in the control
group (P = 0.04). There are reports that azithromycin
causes improved quality of life in patients with cystic
fibrosis and bronchiolitis obliterans (18,19). Ballard et
al. used intravenous azithromycin for prevention of
BPD in a small single center pilot study and showed
significant reductions in length of hospital stay,
duration of mechanical ventilation, and incidence of
treatment with dexamethasone, but no reduction in
incidence of BPD (20). In another study they showed
a decrease in BPD or death in the azithromycin group
who had Ureaplasma urealyticum positive aspirates
(21). Previous studies have suggested that genital
mycolplasmas may contribute to occurrence of BPD in
a proportion of premature infants based on applying
different sampling methods and different diagnostic
tests (14,22-24). The effects of colonization or infection
with Ureaplasma urealyticum on the risk and severity
of BPD remain controversial. Available evidence from
2 small controlled studies does not support the use of
routine testing for this infection in preterm infants or
prophylactic treatment with erythromycin in these
high-risk infants (25). Ureaplasma was implicated
in the development of the pulmonary inflammatory
response observed in infants who progressed to develop
BPD (26). Knowledge of the biology of Ureaplasma
species and their behavior in the respiratory tract
of preterm neonates suggest that lung disease
associated with these organisms is not necessarily
due to direct damage from the bacteria themselves,
but rather because of their potent stimulation of
proinflammatory cytokines or perhaps blockage of
counter-regulatory cytokines (14). The pathogenesis
of BPD is multifactorial and it is often difficult to
determine the effect of one particular risk factor
because of overlap between risk factors. We showed
that oral azithromycin is effective in reducing chronic
oxygen dependency in preterm infants. Although
the reduced incidence of BPD in azithromycin group
infants in our study may suggest a role of mycoplasmas
in the pathogenesis of BPD, it may be due to the
anti-inflammatory effects of azithromycin. Culic et
al. showed that 3-day treatment of healthy human
subjects with standard dose azithromycin exerts acute
effects on the release of neutrophil granular enzymes,
oxidative burst, and oxidative protective mechanisms.
Initial degranulation of circulating neutrophils by
1074

azithromycin is likely to contribute to its antibacterial
effects at sites of infection. However, a more
prolonged degranulation of circulatory neutrophil
could represent a potential anti-inflammatory effect
(15). It is hypothesized that BPD progression results
from antenatal inflammatory exposures that are
dysregulating postnatal inflammation and lung
development (7). We did not find more hepatic side
effects or hearing loss in intervention group neonates
than in the control group during hospitalization and
follow-up. Our patients had received azithromycin for
2 weeks. The exact age of treatment start, appropriate
dose, and duration of treatment with azithromycin for
prevention of BPD are not defined.
Risk factors of BPD including mechanical
ventilation and sepsis had similar frequency among
patients with and without BPD in our study. In our
study, hemodynamically significant PDA was more
common in infants who developed BPD. The lack of
a significant difference among patients who developed
BPD and patients without BPD with respect to
surfactant replacement therapy may be due to the fact
that surfactant became widely available and now is the
standard care in the management of premature infants
with respiratory distress syndrome.
Our study had a limitation in that we did not
collect tracheal aspirates for Ureaplasma urealyticum
culture. Testing for Ureaplasma in clinical practice is
too expensive and the results are often delayed.
Conclusion
Our study suggests that azithromycin in very low birth
weight infants may effectively reduce the incidence
of BPD. Further studies are recommended to assess
the efficacy of this relatively safe treatment in a large
group of patients before any recommendations for its
routine use can be made.
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